Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemi
about
Acute lymphoblastic leukaemiaMinimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologiesPrognostification of ALL by CytogeneticsThe Eleventh International Childhood Acute Lymphoblastic Leukemia Workshop Report: Ponte di Legno, Italy, 6-7 May 2009.Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.Intrachromosomal amplification of chromosome 21 in Korean pediatric patients with B-cell precursor acute lymphoblastic leukemia in a single institution.Immunologic minimal residual disease detection in acute lymphoblastic leukemia: a comparative approach to molecular testingBeyond the 2008 World Health Organization classification: the role of the hematopathology laboratory in the diagnosis and management of acute lymphoblastic leukemiaBiology, risk stratification, and therapy of pediatric acute leukemias: an update.An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome.Recent advances in cancer vaccines: an overview.Survival of Mexican Children with Acute Lymphoblastic Leukaemia under Treatment with the Protocol from the Dana-Farber Cancer Institute 00-01Molecular genetics of B-precursor acute lymphoblastic leukemiaProgress of minimal residual disease studies in childhood acute leukemia.Minimal residual disease in acute lymphoblastic leukemiaIntrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology group.The role of the RAS pathway in iAMP21-ALL.Intrachromosomal amplification of chromosome 21 (iAMP21) detected by ETV6/RUNX1 FISH screening in childhood acute lymphoblastic leukemia: a case report.Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia.Application of flow cytometry in pediatric hematology-oncology.Cytogenetic and molecular predictors of outcome in acute lymphocytic leukemia: recent developments.Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.Predicting relapse risk in childhood acute lymphoblastic leukaemia.High-throughput sequencing for noninvasive disease detection in hematologic malignancies.New genetics and diagnosis of childhood B-cell precursor acute lymphoblastic leukemiaTreatment of Childhood Acute Lymphoblastic Leukemia: Prognostic Factors and Clinical Advances.Possible Mitochondria-Associated Enzymatic Role in Non-Hodgkin Lymphoma Residual Disease.Induction death and treatment-related mortality in first remission of children with acute lymphoblastic leukemia: a population-based analysis of the Austrian Berlin-Frankfurt-Münster study group.Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia.Effective use of small-interfering RNA to characterize residual B-cell non-Hodgkin lymphoma cells following chemotherapy.The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation.Five-year single-center study of asparaginase therapy within the ALL-BFM 2000 trial.Six cases of rare gene amplifications and multiple copy of fusion gene in childhood acute lymphoblastic leukemia.Applicability of gene expression profile of childhood acute lymphoblastic leukemia at diagnosis and at the end of the induction phase of chemotherapy at a cancer hospital in the state of Goiás (Brazil).Redefining treatment failure for pediatric acute leukemia in the era of minimal residual disease testing.Cardiac toxicities of lapatinib in patients with breast cancer and other HER2-positive cancers: a meta-analysis.Dynamic clonal progression in xenografts of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21.B-cell lymphoblastic lymphoma presenting as solitary temporal mass with amplification of AML1/RUNX1: case report.Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000.
P2860
Q24602387-5474A440-FDC8-424A-95AC-6576D7BA1CEEQ26828511-5FA51D12-5326-4446-A09F-18064318D216Q28087446-9DD28C28-86F5-42B6-959B-E801D437277FQ33636082-3E4E7080-6BCB-4528-9B11-B01B92FA698CQ33828575-5F9FA3FE-BFD2-41D1-AD96-07C9D35B4019Q33889940-558F5723-603C-4587-B0E3-2440383122D8Q34425875-F3000608-C793-4445-8211-CEC976546000Q34755687-D8D23DCD-3CE4-4193-B273-2ED0405624F6Q34764504-C2EA8ED3-0390-44B4-8CC6-697D836B0D3AQ34820210-6E02875B-87E4-4D6D-8C0A-DEDA534AD090Q34882348-788BBE68-8766-4755-BA94-FFDB8D1A4AEFQ35437903-09302361-E367-4D3D-971F-EF64A2798E7FQ36290242-BE62D2CA-6DC7-4319-B2FE-FDEBEBF85831Q36981845-BCD856FB-247C-4928-9DC5-FB8AFBD34283Q37077352-ADAB45DA-71DE-419D-8A4D-A50D7AF81B22Q37165093-18300ADA-091E-4F5D-9635-99502E5DFD37Q37245131-8727EE04-4255-4933-9FF7-66873E07229AQ37320741-8EBE97C5-6BFE-4E1B-8621-AFD343E4DCEBQ37389544-6DBB85D5-239E-48A7-83F0-C27E237099D6Q37861074-01D79B9D-47AC-40E1-BD73-6FCE5F685160Q38005040-F1EAF1DF-3E37-44F0-920F-59EC53923211Q38113738-AB24F5AB-D3E1-4530-90AC-5229E3C96B86Q38117685-1D640C98-6831-4CB5-A12D-E5045BE1B25FQ38672646-026AF2C7-0CD6-4501-BF3F-21934AF8F639Q38912335-368EC05C-9AC2-4B8D-AFF5-8187D5628DE8Q38922016-3AA5C41C-8A0B-4C84-B545-59A152A82A5CQ39771036-7986BC6E-8A54-405F-B83D-24556F3D9B7BQ39873557-86B40FAC-AA8B-4A85-939B-267DBDE961CEQ40910460-A57096BF-9B6B-4F3A-BE34-EB6525022761Q41614216-650BF464-7ED3-4D1A-9973-ED872102544FQ41688221-FF1351B3-A324-4262-850E-6A1431A628D7Q44033587-27668FD0-E9DB-44BD-B72A-3CF1FD7EE5BAQ44037161-644EB9BB-AAD7-46A9-906B-F5B83790F953Q44931534-D250983A-CFC8-4DB7-8E43-4081D813A055Q46103668-018FECDD-14D9-4F82-A07C-136B66A31B9DQ48212195-8FBB100A-574E-4A8F-8480-24BF674C7801Q49959951-2A84C86E-78B7-4DC8-93D7-1005A159BDB6Q49966368-DC9418A8-D9A8-4F11-8AB2-1F3D7327A075Q52906689-BDD961C0-21D3-424A-A378-48F0446952C8
P2860
Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemi
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Minimal residual disease value ...... an acute lymphoblastic leukemi
@en
Minimal residual disease value ...... an acute lymphoblastic leukemi
@nl
type
label
Minimal residual disease value ...... an acute lymphoblastic leukemi
@en
Minimal residual disease value ...... an acute lymphoblastic leukemi
@nl
prefLabel
Minimal residual disease value ...... an acute lymphoblastic leukemi
@en
Minimal residual disease value ...... an acute lymphoblastic leukemi
@nl
P2093
P50
P356
P1476
Minimal residual disease value ...... an acute lymphoblastic leukemi
@en
P2093
Andishe Attarbaschi
Anja Möricke
Carsten Reichelt
Dasa Janousek
Eva Csinady
Georg Mann
Helmut Gadner
Jochen Harbott
Manuel Steiner
Margit König
P304
P356
10.1200/JCO.2008.16.1117
P407
P577
2008-06-01T00:00:00Z